[1] Smith TA.FDG uptake,tumor characteristic,and response to therapy:a review[J].Nucl Med Commun,1998,19(2):97-105. [2] Coleman RE.PET in lung cancer[J].J Nucl Med,1999,40(5):814-20. [3] 陈琪,吴湖炳,高蕾,等.恶性淋巴瘤正电子发射型断层扫描技术检查的临床意义[J].第一军医大学学报,2003,23(1):71-3.Chen Q,Wu HB,Gao L,et al.Clinical significance of positron emission tomography for lymphoma patients [J].J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2003,23(1):71-3. [4] Gupta NC,Graeber GM,Bishop HA.Comparative efficacy of positron emission tomography with fluorodeoxy-glucose in evaluation of small (《1 cm),intermediate (1 to3 cm),and large (》3 cm) lymph node lesions[J].Chest,2000,117(3):773-8. [5] Weng E,Tran L,Rege S,et al.Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially respectable lung cancer[J].Am J Clin Oncol,2000,23(1):47-52. [6] Albes JM,Lietzenmayer R,Schott U,et al.Improvement of nonsmall-cell lung cancer staging by means of positron emission tomography[J].Thorac Cardiovasc Surg,1999,47(1):42-7. [7] Yamada Y,Uchida Y,Tatsumi K,et al.Fluorine-18-fluoro- deoxyglucose and carbon-11-methionine evaluation of lympha- denopathy in sarcoidosis[J].J Nucl Med,1998,39(7):1160-6. [8] Matthies A,Hickeson M,Cuchiara A,et al.Dual time point 18F-FDG PET for the evaluation of pulmonary nodules[J].J Nucl Med,2002,43(7):871-5. |